FDA Sees Jump In Number Of Warning Letters For Promotion In 2004
This article was originally published in The Pink Sheet Daily
Executive Summary
CDER's ad division issued 12 warning letters in 2004, "a 250%-300% increase over the typical yearly average," ad division Director Abrams says. FDA is prepared to "do whatever it takes" to get compliance in direct-to-consumer advertising, Abrams declares.
You may also be interested in...
Guidance On Outdoor Promotion Will Formalize "Traditional" Approach – FDA
A draft guidance on outdoor promotion will formalize the Division of Drug Marketing, Advertising & Communications' "traditional" approach to reviewing the advertisements, Director Thomas Abrams said
DTC Ad Comparative Claims Draw FDA Criticism, Even With “Scientific Basis”
“We’re not pleased with the way direct-to-consumer advertising is going,” Acting Commissioner Crawford says. DTC ads have become “ridiculous,” he says; “very strong measures” by FDA may be warranted.
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter